{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:34:37Z","timestamp":1773293677246,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.vaccine.2008.07.006","type":"journal-article","created":{"date-parts":[[2008,7,19]],"date-time":"2008-07-19T08:46:55Z","timestamp":1216457215000},"page":"4655-4663","source":"Crossref","is-referenced-by-count":56,"title":["Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice"],"prefix":"10.1016","volume":"26","author":[{"given":"J. Pradeep","family":"Babu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyabrata","family":"Pattnaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambuj","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsin","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.V. Lakshmana","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2008.07.006_bib1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0966-842X(01)02288-0","article-title":"Epidemic dengue\/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century","volume":"10","author":"Gubler","year":"2002","journal-title":"Trends Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2008.07.006_bib2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1128\/CMR.11.3.480","article-title":"Dengue and dengue hemorrhagic fever","volume":"11","author":"Gubler","year":"1998","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2008.07.006_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0966-842X(99)01669-8","article-title":"The causes and consequences of genetic variation in dengue virus","volume":"8","author":"Holmes","year":"2000","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0065-3527(03)60011-4","article-title":"Neutralization and antibody-dependent enhancement of dengue viruses","volume":"60","author":"Halstead","year":"2003","journal-title":"Adv Virus Res"},{"issue":"4","key":"10.1016\/j.vaccine.2008.07.006_bib5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1086\/499282","article-title":"Antibody-dependent enhancement in dengue virus infections","volume":"193","author":"Burke","year":"2006","journal-title":"J Infect Dis"},{"issue":"21","key":"10.1016\/j.vaccine.2008.07.006_bib6","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.vaccine.2004.11.040","article-title":"Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2008.07.006_bib7","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1099\/0022-1317-82-8-1885","article-title":"Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism","volume":"82","author":"Thullier","year":"2001","journal-title":"J Gen Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2008.07.006_bib8","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1073\/pnas.0832193100","article-title":"A ligand-binding pocket in the dengue virus envelope glycoprotein","volume":"100","author":"Modis","year":"2003","journal-title":"Proc Natl Acad Sci"},{"issue":"16","key":"10.1016\/j.vaccine.2008.07.006_bib9","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1016\/j.vaccine.2006.01.036","article-title":"A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates","volume":"24","author":"Hermida","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.006_bib10","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1128\/JVI.78.1.378-388.2004","article-title":"An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells","volume":"78","author":"Hung","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib11","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1128\/JVI.75.16.7769-7773.2001","article-title":"Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells","volume":"75","author":"Crill","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib12","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1128\/JVI.75.8.4002-4007.2001","article-title":"Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein","volume":"75","author":"Bhardwaj","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib13","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nm0897-866","article-title":"Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate","volume":"3","author":"Chen","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2008.07.006_bib14","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1128\/JVI.75.16.7290-7304.2001","article-title":"Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow feverdengue virus tetravalent vaccine","volume":"75","author":"Guirakhoo","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/viro.2002.1462","article-title":"Viraemia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment and antibody responses against wild-type dengue virus isolates","volume":"298","author":"Guirakhoo","year":"2002","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.vaccine.2008.07.006_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690024","article-title":"Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates","volume":"69","author":"Sun","year":"2003","journal-title":"Am J Trop Med Hyg"},{"issue":"27\/28","key":"10.1016\/j.vaccine.2008.07.006_bib17","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1016\/j.vaccine.2004.03.042","article-title":"Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine","volume":"22","author":"Guy","year":"2004","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2008.07.006_bib18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.inf.0000109289.55856.27","article-title":"Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children","volume":"23","author":"Sabchareon","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.vaccine.2008.07.006_bib19","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/infdis\/174.6.1176","article-title":"Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys","volume":"174","author":"Putnak","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2008.07.006_bib20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0065-3527(03)61010-9","article-title":"Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines","volume":"61","author":"Eckels","year":"2003","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.vaccine.2008.07.006_bib21","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1016\/j.vaccine.2005.03.042","article-title":"An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model","volume":"35","author":"Putnak","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.006_bib22","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.4049\/jimmunol.175.4.2676","article-title":"Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes","volume":"4","author":"Mangada","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690001","article-title":"Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command","volume":"6","author":"Innis","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2008.07.006_bib24","doi-asserted-by":"crossref","first-page":"811","DOI":"10.4269\/ajtmh.2004.71.811","article-title":"Genetically modified, live attenuated dengue virus type 3 vaccine candidates","volume":"6","author":"Blaney","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2008.07.006_bib25","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/427780","article-title":"rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers","volume":"5","author":"Durbin","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2008.07.006_bib26","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1016\/S0264-410X(00)00105-5","article-title":"A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys","volume":"27","author":"Kochel","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.006_bib27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1006\/viro.2001.1136","article-title":"Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF","volume":"1","author":"Raviprakash","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2008.07.006_bib28","first-page":"480","article-title":"Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice","volume":"5","author":"Fonseca","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.006_bib29","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1016\/S0264-410X(00)00121-3","article-title":"Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge","volume":"27","author":"Men","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.006_bib30","doi-asserted-by":"crossref","first-page":"11436","DOI":"10.1128\/JVI.77.21.11436-11447.2003","article-title":"Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development","volume":"21","author":"Huang","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0166-0934(95)01953-7","article-title":"Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with the maltose-binding protein","volume":"2","author":"Staropoli","year":"1996","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2008.07.006_bib32","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/S0264-410X(97)00128-X","article-title":"Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice","volume":"17\/18","author":"Staropoli","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.006_bib33","first-page":"143","article-title":"Designing immune responses with genetic immunization and immunostimulatory DNA sequences","volume":"35","author":"Thalhamer","year":"2001","journal-title":"Endocrine Regul"},{"key":"10.1016\/j.vaccine.2008.07.006_bib34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0264-410X(99)00179-6","article-title":"Over a decade of experience with a Yeast recombinant hepatitis B vaccine","volume":"18","author":"Assad","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.006_bib35","doi-asserted-by":"crossref","first-page":"8266","DOI":"10.1128\/IAI.73.12.8266-8274.2005","article-title":"Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge","volume":"12","author":"Koya","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2008.07.006_bib36","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1016\/j.vaccine.2007.01.068","article-title":"Immunogenicity of a subunit vaccine against Bacillus anthracis","volume":"16","author":"Chichester","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.006_bib37","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1016\/j.vaccine.2007.04.080","article-title":"Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice","volume":"28","author":"Devi","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.006_bib38","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/S0264-410X(00)00032-3","article-title":"Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice","volume":"18","author":"Kelly","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.006_bib39","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.vaccine.2005.11.002","article-title":"Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice","volume":"24","author":"Konishi","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.006_bib40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1472-6750-7-10","article-title":"An adenovirus prime\/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes","volume":"7","author":"Khanam","year":"2007","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib41","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4269\/ajtmh.1998.58.655","article-title":"Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice","volume":"58","author":"Simmons","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2008.07.006_bib42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4269\/ajtmh.2001.65.159","article-title":"Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine","volume":"2","author":"Simmons","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2008.07.006_bib43","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4269\/ajtmh.2006.74.266","article-title":"Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes","volume":"2","author":"Khanam","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2008.07.006_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.micinf.2006.09.009","article-title":"The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry","volume":"9","author":"Chin","year":"2007","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2008.07.006_bib45","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jchromb.2006.08.051","article-title":"Bacterially expressed and refolded envelope protein (domain III) of dengue virus type-4 binds heparan sulfate","volume":"1\/2","author":"Pattnaik","year":"2007","journal-title":"J Chromatogr B"},{"issue":"2","key":"10.1016\/j.vaccine.2008.07.006_bib46","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4049\/jimmunol.99.2.285","article-title":"A plaque reduction test for dengue virus neutralizing antibodies","volume":"99","author":"Russell","year":"1967","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib47","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0264-410X(96)00183-1","article-title":"Adjuvants\u2014a classification and review of their modes of action","volume":"3","author":"Cox","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.006_bib48","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0264-410X(96)00289-7","article-title":"Selection of an adjuvant for vaccination with the malaria antigen, MSA-2","volume":"9","author":"Pye","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.006_bib49","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.4049\/jimmunol.163.12.6448","article-title":"Aluminium hydroxide adjuvant initiates strong antigenspecific Th2 responses in the absence of IL-4- or IL-13-mediated signaling","volume":"163","author":"Brewer","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib50","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/eji.1830260915","article-title":"In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production","volume":"26","author":"Brewer","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib51","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0008-8749(89)90011-7","article-title":"Different T helper cell subsets elicited in mice utilising two different adjuvant vehicles: the role of endogenous IL-1 in proliferative responses","volume":"121","author":"Grun","year":"1989","journal-title":"Cell Immunol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib52","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4269\/ajtmh.1991.45.159","article-title":"Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge","volume":"45","author":"Putnak","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2008.07.006_bib53","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1099\/0022-1317-75-7-1569","article-title":"Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice","volume":"75","author":"Delenda","year":"1994","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib54","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1016\/j.vaccine.2004.12.028","article-title":"Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein","volume":"23","author":"Mota","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.006_bib55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jviromet.2007.02.012","article-title":"High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB\/C mice","volume":"143","author":"Zhang","year":"2007","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2008.07.006_bib56","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0264-410X(94)00059-V","article-title":"Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection","volume":"11","author":"Srivastava","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.07.006_bib57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jviromet.2003.09.024","article-title":"A dengue-2 envelope fragment inserted within the structure of the P64k meningococcal protein carrier, enables a functional immune response against the virus in mice","volume":"115","author":"Hermida","year":"2004","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2008.07.006_bib58","series-title":"Immunology","author":"Roitt","year":"2001"},{"key":"10.1016\/j.vaccine.2008.07.006_bib59","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1006\/viro.1999.9738","article-title":"Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways","volume":"2","author":"Zhou","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2008.07.006_bib60","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1126\/science.8456301","article-title":"Immune response in mice that lack the interferon-gamma receptor","volume":"5102","author":"Huang","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2008.07.006_bib61","doi-asserted-by":"crossref","first-page":"9580","DOI":"10.1128\/JVI.74.20.9580-9585.2000","article-title":"The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus","volume":"20","author":"Stojdl","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib62","first-page":"469","article-title":"Effect of IL-6 and TNF-alpha on Dengue virus infection of human dendritic cells","volume":"4","author":"Shi","year":"2006","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"10.1016\/j.vaccine.2008.07.006_bib63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF01314622","article-title":"Dengue virus infection of human skin fibroblasts in vitro production of IFN-beta, IL-6 and GM-CSF","volume":"1\/2","author":"Kurane","year":"1992","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib64","series-title":"Principles of virology, molecular biology, pathogenesis, and control of animal viruses","author":"Flint","year":"2000"},{"key":"10.1016\/j.vaccine.2008.07.006_bib65","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.iy.07.040189.001045","article-title":"TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties","volume":"7","author":"Mosmann","year":"1989","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib66","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0091-6749(96)80146-1","article-title":"Update on cytokines","volume":"3","author":"Borish","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2008.07.006_bib67","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/0042-6822(92)90450-4","article-title":"Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein","volume":"187","author":"Megret","year":"1992","journal-title":"Virology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08008669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08008669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:28:30Z","timestamp":1684481310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X08008669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":67,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0264410X08008669"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2008.07.006","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}